SICAV

Faron’s Financial Statement Release January 1 to December 31, 2023

Retrieved on: 
Wednesday, March 13, 2024
Head, Q&A, Survival, Immunotherapy, Patient, Medicine, Standard of care, CMML, Macrophage, Faron Pharmaceuticals, Neoplasm, EET, Rheumatology, PD-1, TME, PR, ASH, AML, Cancer, Johnson & Johnson, Safety, Azacitidine, MDS, BLA, Decitabine, Food, ODD, Nasdaq First North, PD, Tumor microenvironment, Manuscript, CRS, SICAV, MD, Interferon beta-1a, Haematopoietic system, GMT, FDA, AIM, Neurotoxicity, Infection, EUR, Sanofi, SOC, Metabolism, European Hematology Association, EDT, MBA, IPF, Facility, Treasury, Society, Cytokine release syndrome, CPA, Pharmaceutical industry

As at March 13, 2024, the Company is in compliance with all IPF financial covenants as agreed with the waiver letter.

Key Points: 
  • As at March 13, 2024, the Company is in compliance with all IPF financial covenants as agreed with the waiver letter.
  • Loss for the period for the financial year ended December 31, 2023, was EUR 30,9 million (2022: EUR 28,7 million).
  • In June 2023, Faron conducted a placement of 2,601,510 newly issued treasury shares to investors to raise EUR 6,6 million gross.
  • In October 2023, the Company successfully raised EUR 7,1 million gross through the issuance of 2,491,998 ordinary shares to investors.

Medical technology back on track

Retrieved on: 
Wednesday, March 13, 2024
Hospital, CNMV, Growth, Annual report, TEL, Cigna, House, Health, Acceleration, Intuitive Surgical, Medtech, Post office box, SICAV, Judgement, Humana, HCA Healthcare, Congress, Environment, Lux, South, Harmony Row, Conference, AG, Medtronic, Capital, Investment, Research, Prospectus, Intelligence, SIX Swiss Exchange, CHF, Intuition, Risk, Medicare, Grand Canal Dock, Pharmaceutical industry

The broad healthcare sector and the medical technology sector, buoyed by resurgent investor interest, delivered even better returns.

Key Points: 
  • The broad healthcare sector and the medical technology sector, buoyed by resurgent investor interest, delivered even better returns.
  • “We also anticipate a big boost in growth from the increasing use of artificial intelligence in the medical technology and healthcare services industries,” Stefan Blum adds.
  • These were generally characterized by strong growth momentum in surgical procedures and an optimistic outlook for the 2024 fiscal year,” Marcel Fritsch comments.
  • Elevance, which is focused on employer-sponsored health insurance plans, reported better-than-expected profits thanks to a drop in medical costs and an increase in management’s earnings guidance for 2024.

Investing in the future of the healthcare industry: Bellevue launches innovative AI Health Fund

Retrieved on: 
Wednesday, January 17, 2024
House, Research, Health care, SIX Swiss Exchange, Risk, AG, Health, Capital, Growth, Harmony Row, South, Grand Canal Dock, Lux, Post office box, Prospectus, UnitedHealth Group, Drug development, Annual report, SICAV, Investment, CNMV, OpenAI, Heart failure, Portfolio, Amgen, TEL, Judgement, PwC, USD, CHF

Investing in the future of the healthcare industry: Bellevue launches innovative AI Health Fund

Key Points: 
  • Investing in the future of the healthcare industry: Bellevue launches innovative AI Health Fund
    Media release of January 15, 2024
    Investing in the future of the healthcare industry: Bellevue launches innovative AI Health Fund
    Generative Artificial Intelligence (GenAI) is bringing about an unprecedented technological transformation.
  • “The investment approach we are taking with the Bellevue AI Health (Lux) Fund that was launched on November 30, 2023 is different.
  • Healthcare will benefit greatly from GenAI,” says Co-Portfolio Manager Stefan Blum, which explains the rationale behind the launch of Bellevue Asset Management's latest healthcare fund.
  • The IT-related risks of implementing AI in healthcare are more calculable than in other industries because healthcare is such a highly regulated market.

Bellevue Asset Management AG: Trend reversal ahead for small and mid caps?

Retrieved on: 
Thursday, December 21, 2023
SIX Swiss Exchange, Annual report, AG, Post office box, House, CHF, University of St. Gallen, Western world, Investment, Lux, CNMV, ECB, Policy, CFA, South, Grand Canal Dock, Government, TEL, Capital, Prospectus, Harmony Row, Research, SICAV, University, War, Judgement, Risk, Pessimism, Fed, Environment, Insurance, Coronavirus, Bank, Cryptocurrency

Bellevue Asset Management AG: Trend reversal ahead for small and mid caps?

Key Points: 
  • Bellevue Asset Management AG: Trend reversal ahead for small and mid caps?
  • Trend reversal ahead for small and mid caps?
  • There is a good chance that small and mid caps will continue to gain ground over large caps.
  • Macro stability in China and the expected winding down of inventory destocking could also add some tailwind to the anticipated trend reversal in small and mid caps.

Bellevue Asset Management AG – Are healthcare stocks poised for a comeback?

Retrieved on: 
Thursday, December 21, 2023
Annual report, Post office box, Vertex Pharmaceuticals, Novo Nordisk, Investment, Capital, Intuitive Surgical, Diabetes, CRISPR Therapeutics, Montreux Healthcare Fund, SIX Swiss Exchange, ChatGPT, Acquisition, Artificial intelligence, Health care, Lux, Growth, AI, Grand Canal Dock, Eli Lilly, Economics, Judgement, Risk, University of Zurich, Clinical trial, AG, House, CNMV, Prospectus, Biotechnology, Hematology, Thermo Fisher Scientific, Doctor of Philosophy, DNA, Genome, Roche, History, Therapy, Failure, Health, D, Patient, Obesity, CHF, Medtech, South, TEL, Harmony Row, Research, SICAV, University, Federal Executive Boards, News, DSM-IV codes, Pharmaceutical industry, Medical device, Cryptocurrency, Libre, Amgen

Bellevue Asset Management AG – Are healthcare stocks poised for a comeback?

Key Points: 
  • Bellevue Asset Management AG – Are healthcare stocks poised for a comeback?
  • In his investment outlook for 2024, Cyrill Zimmermann, a member of Bellevue Asset Management’s Executive Board and Head of Healthcare Funds & Mandates, explains why it is probably only a matter of time before healthcare stocks are rediscovered by the wider investment community.
  • In view of this dynamic situation, Bellevue Asset Management launched Bellevue Obesity Solutions in November, a fund that invests in the most attractive companies across the entire value chain for obesity treatment and management.
  • Dr. Cyrill Zimmermann is Head of Healthcare Funds & Mandates and a member of the Executive Board of Bellevue Asset Management.

Bellevue Asset Management launches Obesity Solutions Fund

Retrieved on: 
Thursday, December 14, 2023
Prospectus, Disease, Nutrition, South, Overweight, Organization, Research, Risk, Capital, WHO, Diagnosis, Investment, COVID-19, Annual report, AG, Lux, Prevalence, TEL, Hospital, UNICEF, Patient, Growth, Grand Canal Dock, SIX Swiss Exchange, CHF, Post office box, SICAV, Harmony Row, Obesity, House, Judgement, CNMV, Clothing, Pharmaceutical industry, Medical device, Cryptocurrency

The Bellevue Obesity Solutions Fund opens a completely new avenue for healthcare investors,» says Christian Lach, the fund's lead portfolio manager.

Key Points: 
  • The Bellevue Obesity Solutions Fund opens a completely new avenue for healthcare investors,» says Christian Lach, the fund's lead portfolio manager.
  • It ranges from obesity prevention, diagnostics, and treatment of obesity to the treatment of myriad related health conditions.
  • Bellevue Obesity Solutions, an actively managed and global equity fund, is exclusively focused on this mega trend.
  • The portfolio management team of the Bellevue Obesity Solutions (Lux) Fund consists of Christian Lach, Lukas Leu and Oliver Kubli, all healthcare investment specialists with many years of experience.

GAMCO Investors, Inc. Reports Results for the Third Quarter 2023

Retrieved on: 
Tuesday, November 7, 2023
Asset, PWM, AUM, Investment, Financial adviser, Cryptocurrency, Commercial property, Heavy equipment, Clothing, Holding company, SICAV, Mutual fund

(b) Includes $230 and $230 of 100% U.S. Treasury Fund AUM at September 30, 2023 and June 30, 2023, respectively.

Key Points: 
  • (b) Includes $230 and $230 of 100% U.S. Treasury Fund AUM at September 30, 2023 and June 30, 2023, respectively.
  • (c) Includes $613 and $579 of the SICAV AUM subadvised by Associated Capital Group, Inc. at September 30, 2023 and June 30, 2023, respectively.
  • Assets under management on September 30, 2023 were $29.2 billion, a decrease of 5.0% from the $30.7 billion on June 30, 2023 reflecting general market trends.
  • Assets under management in SICAV on September 30, 2023 were $622 million, an increase from the $590 million on June 30, 2023.

Golding Capital Partners GmbH: Golding Expands Successful Private Equity Impact Strategy for Article 9 Investors

Retrieved on: 
Tuesday, September 5, 2023
Finance, Environment, Professional Services, Asset Management, Sustainability, Article 9 of the Japanese Constitution, Terra Firma Capital Partners, Golding, SICAV, Classification, Research, Biodiversity loss, Climate change, Investment, European, SFDR, Capital, CIO, Renewable energy, EU

This represents Golding Capital Partners’ response to the increasing demand for investments with ambitious, measurable environmental and social sustainability objectives.

Key Points: 
  • This represents Golding Capital Partners’ response to the increasing demand for investments with ambitious, measurable environmental and social sustainability objectives.
  • This expands the universe of impact funds available to institutional Article 9 investors significantly and also increases the level of diversification substantially.
  • As a result, investors seeking to make Article 9 investments have until now been missing out on these opportunities.
  • This expands the impact universe for institutional Article 9 investors by a significant multiple and enables even greater diversification”, says Dr Matthias Reicherter, Managing Partner and CIO at Golding.

EQS-News: Golding Capital Partners GmbH: Golding expands successful private equity impact strategy for Article 9 investors

Retrieved on: 
Tuesday, September 5, 2023
Article 9 of the Japanese Constitution, Trimaran Capital Partners, Golding, SICAV, Classification, Research, Biodiversity loss, Climate change, Investment, European, SFDR, Capital, CIO, Security (finance), Renewable energy, EU

This represents Golding Capital Partners’ response to the increasing demand for investments with ambitious, measurable environmental and social sustainability objectives.

Key Points: 
  • This represents Golding Capital Partners’ response to the increasing demand for investments with ambitious, measurable environmental and social sustainability objectives.
  • This expands the universe of impact funds available to institutional Article 9 investors significantly and also increases the level of diversification substantially.
  • As a result, investors seeking to make Article 9 investments have until now been missing out on these opportunities.
  • This expands the impact universe for institutional Article 9 investors by a significant multiple and enables even greater diversification”, says Dr Matthias Reicherter, Managing Partner and CIO at Golding.

GAMCO Investors, Inc. Reports Results for the Second Quarter 2023

Retrieved on: 
Tuesday, August 8, 2023
PWM, AUM, Mutual fund, Asset, Investment, SICAV, Financial adviser, Cryptocurrency, Commercial property

(b) Includes $230 and $224 of 100% U.S. Treasury Fund AUM at June 30, 2023 and March 31, 2023, respectively.

Key Points: 
  • (b) Includes $230 and $224 of 100% U.S. Treasury Fund AUM at June 30, 2023 and March 31, 2023, respectively.
  • (c) Includes $579 and $812 of the SICAV AUM subadvised by Associated Capital Group, Inc. at June 30, 2023 and March 31, 2023, respectively.
  • Assets under management at June 30, 2023 were $30.7 billion, unchanged from $30.7 billion at March 31, 2023.
  • Assets under management in Mutual Funds at June 30, 2023 were $8.3 billion, unchanged from March 31, 2023.